Published: Jeffrey Cummings

Dr. Jeffrey Cummings (Brain Health) recently published an article outlining a novel method for determining whether Alzheimer’s drug treatments in clinical trials are ready to move on to the next phase. The paper, “Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach,” was published in The Journal of Dementia and Geriatric Cognitive Disorder

With an estimated 99 percent of drugs in the development pipeline failing, Cummings outlines a semi-qualitative scoring method designed to help identify deficiencies with the goal of decreasing the failure rate and helping bring new therapies to Alzheimer’s patients. His analysis shows that each drug can be analyzed in five critical areas and scored on a scale of 1-5 for a maximum of 25. A drug with a score closer to 25 would be ready for the next phase. Currently, drugs that are moved ahead despite a low score are at a high risk for failure.

People in the News

portrait of Matthew Montalto, Admissions Analyst, Graduate College. 
People | August 10, 2020
It may not be the theater Matthew Montalto once dreamed of working in, but the admissions analyst loves his job at the UNLV Graduate College.
Nicole Santero at home, surrounded by BTS memorabilia, including a poster.
People | August 3, 2020
Nicole Santero balances her job communicating about the School of Public Health with her doctoral research on the BTS phenomenon.
Portrait of Steven Palazzo, the UNLV Schoool of Nursing's new associate dean for academic affairs
People | July 27, 2020
The nurse/educator sees the remote learning necessitated by the pandemic as an opportunity for growth.